Global PD-1&PD-L1 Immunotherapy Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global PD-1&PD-L1 Immunotherapy market size was valued at US$ million in 2023. With growing demand in downstream market, the PD-1&PD-L1 Immunotherapy is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global PD-1&PD-L1 Immunotherapy market. PD-1&PD-L1 Immunotherapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of PD-1&PD-L1 Immunotherapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the PD-1&PD-L1 Immunotherapy market.
A protein found on T cells (a type of immune cell) that helps keep the body's immune responses in check. When PD-1 is bound to another protein called PD-L1, it helps keep T cells from killing other cells, including cancer cells. Some anticancer drugs, called immune checkpoint inhibitors, are used to block PD-1.
Key Features:
The report on PD-1&PD-L1 Immunotherapy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the PD-1&PD-L1 Immunotherapy market. It may include historical data, market segmentation by Type (e.g., PD-1 Inhibitors, PD-L1 Inhibitors), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the PD-1&PD-L1 Immunotherapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the PD-1&PD-L1 Immunotherapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the PD-1&PD-L1 Immunotherapy industry. This include advancements in PD-1&PD-L1 Immunotherapy technology, PD-1&PD-L1 Immunotherapy new entrants, PD-1&PD-L1 Immunotherapy new investment, and other innovations that are shaping the future of PD-1&PD-L1 Immunotherapy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the PD-1&PD-L1 Immunotherapy market. It includes factors influencing customer ' purchasing decisions, preferences for PD-1&PD-L1 Immunotherapy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the PD-1&PD-L1 Immunotherapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting PD-1&PD-L1 Immunotherapy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the PD-1&PD-L1 Immunotherapy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the PD-1&PD-L1 Immunotherapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the PD-1&PD-L1 Immunotherapy market.
Market Segmentation:
PD-1&PD-L1 Immunotherapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global PD-1&PD-L1 Immunotherapy market?
What factors are driving PD-1&PD-L1 Immunotherapy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1&PD-L1 Immunotherapy market opportunities vary by end market size?
How does PD-1&PD-L1 Immunotherapy break out type, application?
According to our LPI (LP Information) latest study, the global PD-1&PD-L1 Immunotherapy market size was valued at US$ million in 2023. With growing demand in downstream market, the PD-1&PD-L1 Immunotherapy is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global PD-1&PD-L1 Immunotherapy market. PD-1&PD-L1 Immunotherapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of PD-1&PD-L1 Immunotherapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the PD-1&PD-L1 Immunotherapy market.
A protein found on T cells (a type of immune cell) that helps keep the body's immune responses in check. When PD-1 is bound to another protein called PD-L1, it helps keep T cells from killing other cells, including cancer cells. Some anticancer drugs, called immune checkpoint inhibitors, are used to block PD-1.
Key Features:
The report on PD-1&PD-L1 Immunotherapy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the PD-1&PD-L1 Immunotherapy market. It may include historical data, market segmentation by Type (e.g., PD-1 Inhibitors, PD-L1 Inhibitors), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the PD-1&PD-L1 Immunotherapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the PD-1&PD-L1 Immunotherapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the PD-1&PD-L1 Immunotherapy industry. This include advancements in PD-1&PD-L1 Immunotherapy technology, PD-1&PD-L1 Immunotherapy new entrants, PD-1&PD-L1 Immunotherapy new investment, and other innovations that are shaping the future of PD-1&PD-L1 Immunotherapy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the PD-1&PD-L1 Immunotherapy market. It includes factors influencing customer ' purchasing decisions, preferences for PD-1&PD-L1 Immunotherapy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the PD-1&PD-L1 Immunotherapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting PD-1&PD-L1 Immunotherapy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the PD-1&PD-L1 Immunotherapy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the PD-1&PD-L1 Immunotherapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the PD-1&PD-L1 Immunotherapy market.
Market Segmentation:
PD-1&PD-L1 Immunotherapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- PD-1 Inhibitors
- PD-L1 Inhibitors
- Non-Small Cell Lung Cancer
- Esophageal Cancer
- Urothelial Carcinoma
- Hepatocellular Carcinoma
- Small Cell Lung Cancer
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca Plc
- BeiGene, Ltd.
- Bristol-Myers Squibb Company
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Eli Lilly & Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Innovent Biologics, Inc.
- Jiangsu HengRui Medicine Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
What is the 10-year outlook for the global PD-1&PD-L1 Immunotherapy market?
What factors are driving PD-1&PD-L1 Immunotherapy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1&PD-L1 Immunotherapy market opportunities vary by end market size?
How does PD-1&PD-L1 Immunotherapy break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1&PD-L1 Immunotherapy Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for PD-1&PD-L1 Immunotherapy by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for PD-1&PD-L1 Immunotherapy by Country/Region, 2019, 2023 & 2030
2.2 PD-1&PD-L1 Immunotherapy Segment by Type
2.2.1 PD-1 Inhibitors
2.2.2 PD-L1 Inhibitors
2.3 PD-1&PD-L1 Immunotherapy Sales by Type
2.3.1 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
2.3.2 Global PD-1&PD-L1 Immunotherapy Revenue and Market Share by Type (2019-2024)
2.3.3 Global PD-1&PD-L1 Immunotherapy Sale Price by Type (2019-2024)
2.4 PD-1&PD-L1 Immunotherapy Segment by Application
2.4.1 Non-Small Cell Lung Cancer
2.4.2 Esophageal Cancer
2.4.3 Urothelial Carcinoma
2.4.4 Hepatocellular Carcinoma
2.4.5 Small Cell Lung Cancer
2.4.6 Others
2.5 PD-1&PD-L1 Immunotherapy Sales by Application
2.5.1 Global PD-1&PD-L1 Immunotherapy Sale Market Share by Application (2019-2024)
2.5.2 Global PD-1&PD-L1 Immunotherapy Revenue and Market Share by Application (2019-2024)
2.5.3 Global PD-1&PD-L1 Immunotherapy Sale Price by Application (2019-2024)
3 GLOBAL PD-1&PD-L1 IMMUNOTHERAPY BY COMPANY
3.1 Global PD-1&PD-L1 Immunotherapy Breakdown Data by Company
3.1.1 Global PD-1&PD-L1 Immunotherapy Annual Sales by Company (2019-2024)
3.1.2 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Company (2019-2024)
3.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue by Company (2019-2024)
3.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Company (2019-2024)
3.2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Company (2019-2024)
3.3 Global PD-1&PD-L1 Immunotherapy Sale Price by Company
3.4 Key Manufacturers PD-1&PD-L1 Immunotherapy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1&PD-L1 Immunotherapy Product Location Distribution
3.4.2 Players PD-1&PD-L1 Immunotherapy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PD-1&PD-L1 IMMUNOTHERAPY BY GEOGRAPHIC REGION
4.1 World Historic PD-1&PD-L1 Immunotherapy Market Size by Geographic Region (2019-2024)
4.1.1 Global PD-1&PD-L1 Immunotherapy Annual Sales by Geographic Region (2019-2024)
4.1.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic PD-1&PD-L1 Immunotherapy Market Size by Country/Region (2019-2024)
4.2.1 Global PD-1&PD-L1 Immunotherapy Annual Sales by Country/Region (2019-2024)
4.2.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas PD-1&PD-L1 Immunotherapy Sales Growth
4.4 APAC PD-1&PD-L1 Immunotherapy Sales Growth
4.5 Europe PD-1&PD-L1 Immunotherapy Sales Growth
4.6 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Growth
5 AMERICAS
5.1 Americas PD-1&PD-L1 Immunotherapy Sales by Country
5.1.1 Americas PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024)
5.1.2 Americas PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024)
5.2 Americas PD-1&PD-L1 Immunotherapy Sales by Type
5.3 Americas PD-1&PD-L1 Immunotherapy Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1&PD-L1 Immunotherapy Sales by Region
6.1.1 APAC PD-1&PD-L1 Immunotherapy Sales by Region (2019-2024)
6.1.2 APAC PD-1&PD-L1 Immunotherapy Revenue by Region (2019-2024)
6.2 APAC PD-1&PD-L1 Immunotherapy Sales by Type
6.3 APAC PD-1&PD-L1 Immunotherapy Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1&PD-L1 Immunotherapy by Country
7.1.1 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024)
7.1.2 Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024)
7.2 Europe PD-1&PD-L1 Immunotherapy Sales by Type
7.3 Europe PD-1&PD-L1 Immunotherapy Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1&PD-L1 Immunotherapy by Country
8.1.1 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024)
8.1.2 Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024)
8.2 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Type
8.3 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1&PD-L1 Immunotherapy
10.3 Manufacturing Process Analysis of PD-1&PD-L1 Immunotherapy
10.4 Industry Chain Structure of PD-1&PD-L1 Immunotherapy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1&PD-L1 Immunotherapy Distributors
11.3 PD-1&PD-L1 Immunotherapy Customer
12 WORLD FORECAST REVIEW FOR PD-1&PD-L1 IMMUNOTHERAPY BY GEOGRAPHIC REGION
12.1 Global PD-1&PD-L1 Immunotherapy Market Size Forecast by Region
12.1.1 Global PD-1&PD-L1 Immunotherapy Forecast by Region (2025-2030)
12.1.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PD-1&PD-L1 Immunotherapy Forecast by Type
12.7 Global PD-1&PD-L1 Immunotherapy Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca Plc
13.1.1 AstraZeneca Plc Company Information
13.1.2 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AstraZeneca Plc Main Business Overview
13.1.5 AstraZeneca Plc Latest Developments
13.2 BeiGene, Ltd.
13.2.1 BeiGene, Ltd. Company Information
13.2.2 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 BeiGene, Ltd. Main Business Overview
13.2.5 BeiGene, Ltd. Latest Developments
13.3 Bristol-Myers Squibb Company
13.3.1 Bristol-Myers Squibb Company Company Information
13.3.2 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bristol-Myers Squibb Company Main Business Overview
13.3.5 Bristol-Myers Squibb Company Latest Developments
13.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
13.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
13.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Main Business Overview
13.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Latest Developments
13.5 Eli Lilly & Company
13.5.1 Eli Lilly & Company Company Information
13.5.2 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Eli Lilly & Company Main Business Overview
13.5.5 Eli Lilly & Company Latest Developments
13.6 F. Hoffmann-La Roche Ltd
13.6.1 F. Hoffmann-La Roche Ltd Company Information
13.6.2 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.6.5 F. Hoffmann-La Roche Ltd Latest Developments
13.7 GlaxoSmithKline plc
13.7.1 GlaxoSmithKline plc Company Information
13.7.2 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 GlaxoSmithKline plc Main Business Overview
13.7.5 GlaxoSmithKline plc Latest Developments
13.8 Innovent Biologics, Inc.
13.8.1 Innovent Biologics, Inc. Company Information
13.8.2 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Biologics, Inc. Main Business Overview
13.8.5 Innovent Biologics, Inc. Latest Developments
13.9 Jiangsu HengRui Medicine Co., Ltd.
13.9.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
13.9.2 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview
13.9.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments
13.10 Merck & Co., Inc.
13.10.1 Merck & Co., Inc. Company Information
13.10.2 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Merck & Co., Inc. Main Business Overview
13.10.5 Merck & Co., Inc. Latest Developments
13.11 Novartis AG
13.11.1 Novartis AG Company Information
13.11.2 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Novartis AG Main Business Overview
13.11.5 Novartis AG Latest Developments
13.12 Pfizer Inc.
13.12.1 Pfizer Inc. Company Information
13.12.2 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Pfizer Inc. Main Business Overview
13.12.5 Pfizer Inc. Latest Developments
13.13 Regeneron Pharmaceuticals Inc.
13.13.1 Regeneron Pharmaceuticals Inc. Company Information
13.13.2 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Regeneron Pharmaceuticals Inc. Main Business Overview
13.13.5 Regeneron Pharmaceuticals Inc. Latest Developments
13.14 Sanofi S.A.
13.14.1 Sanofi S.A. Company Information
13.14.2 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Sanofi S.A. Main Business Overview
13.14.5 Sanofi S.A. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1&PD-L1 Immunotherapy Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for PD-1&PD-L1 Immunotherapy by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for PD-1&PD-L1 Immunotherapy by Country/Region, 2019, 2023 & 2030
2.2 PD-1&PD-L1 Immunotherapy Segment by Type
2.2.1 PD-1 Inhibitors
2.2.2 PD-L1 Inhibitors
2.3 PD-1&PD-L1 Immunotherapy Sales by Type
2.3.1 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
2.3.2 Global PD-1&PD-L1 Immunotherapy Revenue and Market Share by Type (2019-2024)
2.3.3 Global PD-1&PD-L1 Immunotherapy Sale Price by Type (2019-2024)
2.4 PD-1&PD-L1 Immunotherapy Segment by Application
2.4.1 Non-Small Cell Lung Cancer
2.4.2 Esophageal Cancer
2.4.3 Urothelial Carcinoma
2.4.4 Hepatocellular Carcinoma
2.4.5 Small Cell Lung Cancer
2.4.6 Others
2.5 PD-1&PD-L1 Immunotherapy Sales by Application
2.5.1 Global PD-1&PD-L1 Immunotherapy Sale Market Share by Application (2019-2024)
2.5.2 Global PD-1&PD-L1 Immunotherapy Revenue and Market Share by Application (2019-2024)
2.5.3 Global PD-1&PD-L1 Immunotherapy Sale Price by Application (2019-2024)
3 GLOBAL PD-1&PD-L1 IMMUNOTHERAPY BY COMPANY
3.1 Global PD-1&PD-L1 Immunotherapy Breakdown Data by Company
3.1.1 Global PD-1&PD-L1 Immunotherapy Annual Sales by Company (2019-2024)
3.1.2 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Company (2019-2024)
3.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue by Company (2019-2024)
3.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Company (2019-2024)
3.2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Company (2019-2024)
3.3 Global PD-1&PD-L1 Immunotherapy Sale Price by Company
3.4 Key Manufacturers PD-1&PD-L1 Immunotherapy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1&PD-L1 Immunotherapy Product Location Distribution
3.4.2 Players PD-1&PD-L1 Immunotherapy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PD-1&PD-L1 IMMUNOTHERAPY BY GEOGRAPHIC REGION
4.1 World Historic PD-1&PD-L1 Immunotherapy Market Size by Geographic Region (2019-2024)
4.1.1 Global PD-1&PD-L1 Immunotherapy Annual Sales by Geographic Region (2019-2024)
4.1.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic PD-1&PD-L1 Immunotherapy Market Size by Country/Region (2019-2024)
4.2.1 Global PD-1&PD-L1 Immunotherapy Annual Sales by Country/Region (2019-2024)
4.2.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas PD-1&PD-L1 Immunotherapy Sales Growth
4.4 APAC PD-1&PD-L1 Immunotherapy Sales Growth
4.5 Europe PD-1&PD-L1 Immunotherapy Sales Growth
4.6 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Growth
5 AMERICAS
5.1 Americas PD-1&PD-L1 Immunotherapy Sales by Country
5.1.1 Americas PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024)
5.1.2 Americas PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024)
5.2 Americas PD-1&PD-L1 Immunotherapy Sales by Type
5.3 Americas PD-1&PD-L1 Immunotherapy Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1&PD-L1 Immunotherapy Sales by Region
6.1.1 APAC PD-1&PD-L1 Immunotherapy Sales by Region (2019-2024)
6.1.2 APAC PD-1&PD-L1 Immunotherapy Revenue by Region (2019-2024)
6.2 APAC PD-1&PD-L1 Immunotherapy Sales by Type
6.3 APAC PD-1&PD-L1 Immunotherapy Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1&PD-L1 Immunotherapy by Country
7.1.1 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024)
7.1.2 Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024)
7.2 Europe PD-1&PD-L1 Immunotherapy Sales by Type
7.3 Europe PD-1&PD-L1 Immunotherapy Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1&PD-L1 Immunotherapy by Country
8.1.1 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024)
8.1.2 Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024)
8.2 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Type
8.3 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1&PD-L1 Immunotherapy
10.3 Manufacturing Process Analysis of PD-1&PD-L1 Immunotherapy
10.4 Industry Chain Structure of PD-1&PD-L1 Immunotherapy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1&PD-L1 Immunotherapy Distributors
11.3 PD-1&PD-L1 Immunotherapy Customer
12 WORLD FORECAST REVIEW FOR PD-1&PD-L1 IMMUNOTHERAPY BY GEOGRAPHIC REGION
12.1 Global PD-1&PD-L1 Immunotherapy Market Size Forecast by Region
12.1.1 Global PD-1&PD-L1 Immunotherapy Forecast by Region (2025-2030)
12.1.2 Global PD-1&PD-L1 Immunotherapy Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PD-1&PD-L1 Immunotherapy Forecast by Type
12.7 Global PD-1&PD-L1 Immunotherapy Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca Plc
13.1.1 AstraZeneca Plc Company Information
13.1.2 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AstraZeneca Plc Main Business Overview
13.1.5 AstraZeneca Plc Latest Developments
13.2 BeiGene, Ltd.
13.2.1 BeiGene, Ltd. Company Information
13.2.2 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 BeiGene, Ltd. Main Business Overview
13.2.5 BeiGene, Ltd. Latest Developments
13.3 Bristol-Myers Squibb Company
13.3.1 Bristol-Myers Squibb Company Company Information
13.3.2 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bristol-Myers Squibb Company Main Business Overview
13.3.5 Bristol-Myers Squibb Company Latest Developments
13.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
13.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
13.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Main Business Overview
13.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Latest Developments
13.5 Eli Lilly & Company
13.5.1 Eli Lilly & Company Company Information
13.5.2 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Eli Lilly & Company Main Business Overview
13.5.5 Eli Lilly & Company Latest Developments
13.6 F. Hoffmann-La Roche Ltd
13.6.1 F. Hoffmann-La Roche Ltd Company Information
13.6.2 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.6.5 F. Hoffmann-La Roche Ltd Latest Developments
13.7 GlaxoSmithKline plc
13.7.1 GlaxoSmithKline plc Company Information
13.7.2 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 GlaxoSmithKline plc Main Business Overview
13.7.5 GlaxoSmithKline plc Latest Developments
13.8 Innovent Biologics, Inc.
13.8.1 Innovent Biologics, Inc. Company Information
13.8.2 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Biologics, Inc. Main Business Overview
13.8.5 Innovent Biologics, Inc. Latest Developments
13.9 Jiangsu HengRui Medicine Co., Ltd.
13.9.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
13.9.2 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview
13.9.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments
13.10 Merck & Co., Inc.
13.10.1 Merck & Co., Inc. Company Information
13.10.2 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Merck & Co., Inc. Main Business Overview
13.10.5 Merck & Co., Inc. Latest Developments
13.11 Novartis AG
13.11.1 Novartis AG Company Information
13.11.2 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Novartis AG Main Business Overview
13.11.5 Novartis AG Latest Developments
13.12 Pfizer Inc.
13.12.1 Pfizer Inc. Company Information
13.12.2 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Pfizer Inc. Main Business Overview
13.12.5 Pfizer Inc. Latest Developments
13.13 Regeneron Pharmaceuticals Inc.
13.13.1 Regeneron Pharmaceuticals Inc. Company Information
13.13.2 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Regeneron Pharmaceuticals Inc. Main Business Overview
13.13.5 Regeneron Pharmaceuticals Inc. Latest Developments
13.14 Sanofi S.A.
13.14.1 Sanofi S.A. Company Information
13.14.2 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
13.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Sanofi S.A. Main Business Overview
13.14.5 Sanofi S.A. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. PD-1&PD-L1 Immunotherapy Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. PD-1&PD-L1 Immunotherapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of PD-1 Inhibitors
Table 4. Major Players of PD-L1 Inhibitors
Table 5. Global PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 6. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Table 7. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2019-2024) & ($ million)
Table 8. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2019-2024)
Table 9. Global PD-1&PD-L1 Immunotherapy Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 11. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Table 12. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2019-2024)
Table 13. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2019-2024)
Table 14. Global PD-1&PD-L1 Immunotherapy Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global PD-1&PD-L1 Immunotherapy Sales by Company (2019-2024) & (Units)
Table 16. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Company (2019-2024)
Table 17. Global PD-1&PD-L1 Immunotherapy Revenue by Company (2019-2024) ($ Millions)
Table 18. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Company (2019-2024)
Table 19. Global PD-1&PD-L1 Immunotherapy Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers PD-1&PD-L1 Immunotherapy Producing Area Distribution and Sales Area
Table 21. Players PD-1&PD-L1 Immunotherapy Products Offered
Table 22. PD-1&PD-L1 Immunotherapy Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global PD-1&PD-L1 Immunotherapy Sales by Geographic Region (2019-2024) & (Units)
Table 26. Global PD-1&PD-L1 Immunotherapy Sales Market Share Geographic Region (2019-2024)
Table 27. Global PD-1&PD-L1 Immunotherapy Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global PD-1&PD-L1 Immunotherapy Sales by Country/Region (2019-2024) & (Units)
Table 30. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Country/Region (2019-2024)
Table 31. Global PD-1&PD-L1 Immunotherapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024) & (Units)
Table 34. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2019-2024)
Table 35. Americas PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2019-2024)
Table 37. Americas PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 38. Americas PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 39. APAC PD-1&PD-L1 Immunotherapy Sales by Region (2019-2024) & (Units)
Table 40. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2019-2024)
Table 41. APAC PD-1&PD-L1 Immunotherapy Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2019-2024)
Table 43. APAC PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 44. APAC PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 45. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024) & (Units)
Table 46. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2019-2024)
Table 47. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2019-2024)
Table 49. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 50. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 51. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024) & (Units)
Table 52. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 56. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of PD-1&PD-L1 Immunotherapy
Table 58. Key Market Challenges & Risks of PD-1&PD-L1 Immunotherapy
Table 59. Key Industry Trends of PD-1&PD-L1 Immunotherapy
Table 60. PD-1&PD-L1 Immunotherapy Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. PD-1&PD-L1 Immunotherapy Distributors List
Table 63. PD-1&PD-L1 Immunotherapy Customer List
Table 64. Global PD-1&PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (Units)
Table 65. Global PD-1&PD-L1 Immunotherapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (Units)
Table 67. Americas PD-1&PD-L1 Immunotherapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC PD-1&PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (Units)
Table 69. APAC PD-1&PD-L1 Immunotherapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (Units)
Table 71. Europe PD-1&PD-L1 Immunotherapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (Units)
Table 73. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global PD-1&PD-L1 Immunotherapy Sales Forecast by Type (2025-2030) & (Units)
Table 75. Global PD-1&PD-L1 Immunotherapy Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global PD-1&PD-L1 Immunotherapy Sales Forecast by Application (2025-2030) & (Units)
Table 77. Global PD-1&PD-L1 Immunotherapy Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. AstraZeneca Plc Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 80. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. AstraZeneca Plc Main Business
Table 82. AstraZeneca Plc Latest Developments
Table 83. BeiGene, Ltd. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 84. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 85. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. BeiGene, Ltd. Main Business
Table 87. BeiGene, Ltd. Latest Developments
Table 88. Bristol-Myers Squibb Company Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 89. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 90. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Bristol-Myers Squibb Company Main Business
Table 92. Bristol-Myers Squibb Company Latest Developments
Table 93. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 94. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 95. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Main Business
Table 97. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Latest Developments
Table 98. Eli Lilly & Company Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 99. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 100. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 101. Eli Lilly & Company Main Business
Table 102. Eli Lilly & Company Latest Developments
Table 103. F. Hoffmann-La Roche Ltd Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 104. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 105. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 106. F. Hoffmann-La Roche Ltd Main Business
Table 107. F. Hoffmann-La Roche Ltd Latest Developments
Table 108. GlaxoSmithKline plc Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 109. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 110. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. GlaxoSmithKline plc Main Business
Table 112. GlaxoSmithKline plc Latest Developments
Table 113. Innovent Biologics, Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 114. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 115. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. Innovent Biologics, Inc. Main Business
Table 117. Innovent Biologics, Inc. Latest Developments
Table 118. Jiangsu HengRui Medicine Co., Ltd. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 119. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 120. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 121. Jiangsu HengRui Medicine Co., Ltd. Main Business
Table 122. Jiangsu HengRui Medicine Co., Ltd. Latest Developments
Table 123. Merck & Co., Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 125. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 126. Merck & Co., Inc. Main Business
Table 127. Merck & Co., Inc. Latest Developments
Table 128. Novartis AG Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 129. Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 130. Novartis AG PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 131. Novartis AG Main Business
Table 132. Novartis AG Latest Developments
Table 133. Pfizer Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 134. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 135. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 136. Pfizer Inc. Main Business
Table 137. Pfizer Inc. Latest Developments
Table 138. Regeneron Pharmaceuticals Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 139. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 140. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 141. Regeneron Pharmaceuticals Inc. Main Business
Table 142. Regeneron Pharmaceuticals Inc. Latest Developments
Table 143. Sanofi S.A. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 144. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 145. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 146. Sanofi S.A. Main Business
Table 147. Sanofi S.A. Latest Developments
Table 1. PD-1&PD-L1 Immunotherapy Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. PD-1&PD-L1 Immunotherapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of PD-1 Inhibitors
Table 4. Major Players of PD-L1 Inhibitors
Table 5. Global PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 6. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Table 7. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2019-2024) & ($ million)
Table 8. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2019-2024)
Table 9. Global PD-1&PD-L1 Immunotherapy Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 11. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Table 12. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2019-2024)
Table 13. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2019-2024)
Table 14. Global PD-1&PD-L1 Immunotherapy Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global PD-1&PD-L1 Immunotherapy Sales by Company (2019-2024) & (Units)
Table 16. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Company (2019-2024)
Table 17. Global PD-1&PD-L1 Immunotherapy Revenue by Company (2019-2024) ($ Millions)
Table 18. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Company (2019-2024)
Table 19. Global PD-1&PD-L1 Immunotherapy Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers PD-1&PD-L1 Immunotherapy Producing Area Distribution and Sales Area
Table 21. Players PD-1&PD-L1 Immunotherapy Products Offered
Table 22. PD-1&PD-L1 Immunotherapy Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global PD-1&PD-L1 Immunotherapy Sales by Geographic Region (2019-2024) & (Units)
Table 26. Global PD-1&PD-L1 Immunotherapy Sales Market Share Geographic Region (2019-2024)
Table 27. Global PD-1&PD-L1 Immunotherapy Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global PD-1&PD-L1 Immunotherapy Sales by Country/Region (2019-2024) & (Units)
Table 30. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Country/Region (2019-2024)
Table 31. Global PD-1&PD-L1 Immunotherapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024) & (Units)
Table 34. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2019-2024)
Table 35. Americas PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2019-2024)
Table 37. Americas PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 38. Americas PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 39. APAC PD-1&PD-L1 Immunotherapy Sales by Region (2019-2024) & (Units)
Table 40. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2019-2024)
Table 41. APAC PD-1&PD-L1 Immunotherapy Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2019-2024)
Table 43. APAC PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 44. APAC PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 45. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024) & (Units)
Table 46. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2019-2024)
Table 47. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2019-2024)
Table 49. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 50. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 51. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Country (2019-2024) & (Units)
Table 52. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024) & (Units)
Table 56. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of PD-1&PD-L1 Immunotherapy
Table 58. Key Market Challenges & Risks of PD-1&PD-L1 Immunotherapy
Table 59. Key Industry Trends of PD-1&PD-L1 Immunotherapy
Table 60. PD-1&PD-L1 Immunotherapy Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. PD-1&PD-L1 Immunotherapy Distributors List
Table 63. PD-1&PD-L1 Immunotherapy Customer List
Table 64. Global PD-1&PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (Units)
Table 65. Global PD-1&PD-L1 Immunotherapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (Units)
Table 67. Americas PD-1&PD-L1 Immunotherapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC PD-1&PD-L1 Immunotherapy Sales Forecast by Region (2025-2030) & (Units)
Table 69. APAC PD-1&PD-L1 Immunotherapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (Units)
Table 71. Europe PD-1&PD-L1 Immunotherapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Forecast by Country (2025-2030) & (Units)
Table 73. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global PD-1&PD-L1 Immunotherapy Sales Forecast by Type (2025-2030) & (Units)
Table 75. Global PD-1&PD-L1 Immunotherapy Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global PD-1&PD-L1 Immunotherapy Sales Forecast by Application (2025-2030) & (Units)
Table 77. Global PD-1&PD-L1 Immunotherapy Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. AstraZeneca Plc Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 80. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. AstraZeneca Plc Main Business
Table 82. AstraZeneca Plc Latest Developments
Table 83. BeiGene, Ltd. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 84. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 85. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. BeiGene, Ltd. Main Business
Table 87. BeiGene, Ltd. Latest Developments
Table 88. Bristol-Myers Squibb Company Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 89. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 90. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Bristol-Myers Squibb Company Main Business
Table 92. Bristol-Myers Squibb Company Latest Developments
Table 93. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 94. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 95. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Main Business
Table 97. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Latest Developments
Table 98. Eli Lilly & Company Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 99. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 100. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 101. Eli Lilly & Company Main Business
Table 102. Eli Lilly & Company Latest Developments
Table 103. F. Hoffmann-La Roche Ltd Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 104. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 105. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 106. F. Hoffmann-La Roche Ltd Main Business
Table 107. F. Hoffmann-La Roche Ltd Latest Developments
Table 108. GlaxoSmithKline plc Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 109. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 110. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. GlaxoSmithKline plc Main Business
Table 112. GlaxoSmithKline plc Latest Developments
Table 113. Innovent Biologics, Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 114. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 115. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. Innovent Biologics, Inc. Main Business
Table 117. Innovent Biologics, Inc. Latest Developments
Table 118. Jiangsu HengRui Medicine Co., Ltd. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 119. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 120. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 121. Jiangsu HengRui Medicine Co., Ltd. Main Business
Table 122. Jiangsu HengRui Medicine Co., Ltd. Latest Developments
Table 123. Merck & Co., Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 125. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 126. Merck & Co., Inc. Main Business
Table 127. Merck & Co., Inc. Latest Developments
Table 128. Novartis AG Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 129. Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 130. Novartis AG PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 131. Novartis AG Main Business
Table 132. Novartis AG Latest Developments
Table 133. Pfizer Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 134. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 135. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 136. Pfizer Inc. Main Business
Table 137. Pfizer Inc. Latest Developments
Table 138. Regeneron Pharmaceuticals Inc. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 139. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 140. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 141. Regeneron Pharmaceuticals Inc. Main Business
Table 142. Regeneron Pharmaceuticals Inc. Latest Developments
Table 143. Sanofi S.A. Basic Information, PD-1&PD-L1 Immunotherapy Manufacturing Base, Sales Area and Its Competitors
Table 144. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolios and Specifications
Table 145. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 146. Sanofi S.A. Main Business
Table 147. Sanofi S.A. Latest Developments
LIST OF FIGURES
Figure 1. Picture of PD-1&PD-L1 Immunotherapy
Figure 2. PD-1&PD-L1 Immunotherapy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1&PD-L1 Immunotherapy Sales Growth Rate 2019-2030 (Units)
Figure 7. Global PD-1&PD-L1 Immunotherapy Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. PD-1&PD-L1 Immunotherapy Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of PD-1 Inhibitors
Figure 10. Product Picture of PD-L1 Inhibitors
Figure 11. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type in 2023
Figure 12. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2019-2024)
Figure 13. PD-1&PD-L1 Immunotherapy Consumed in Non-Small Cell Lung Cancer
Figure 14. Global PD-1&PD-L1 Immunotherapy Market: Non-Small Cell Lung Cancer (2019-2024) & (Units)
Figure 15. PD-1&PD-L1 Immunotherapy Consumed in Esophageal Cancer
Figure 16. Global PD-1&PD-L1 Immunotherapy Market: Esophageal Cancer (2019-2024) & (Units)
Figure 17. PD-1&PD-L1 Immunotherapy Consumed in Urothelial Carcinoma
Figure 18. Global PD-1&PD-L1 Immunotherapy Market: Urothelial Carcinoma (2019-2024) & (Units)
Figure 19. PD-1&PD-L1 Immunotherapy Consumed in Hepatocellular Carcinoma
Figure 20. Global PD-1&PD-L1 Immunotherapy Market: Hepatocellular Carcinoma (2019-2024) & (Units)
Figure 21. PD-1&PD-L1 Immunotherapy Consumed in Small Cell Lung Cancer
Figure 22. Global PD-1&PD-L1 Immunotherapy Market: Small Cell Lung Cancer (2019-2024) & (Units)
Figure 23. PD-1&PD-L1 Immunotherapy Consumed in Others
Figure 24. Global PD-1&PD-L1 Immunotherapy Market: Others (2019-2024) & (Units)
Figure 25. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2023)
Figure 26. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application in 2023
Figure 27. PD-1&PD-L1 Immunotherapy Sales Market by Company in 2023 (Units)
Figure 28. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Company in 2023
Figure 29. PD-1&PD-L1 Immunotherapy Revenue Market by Company in 2023 ($ Million)
Figure 30. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Company in 2023
Figure 31. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Geographic Region in 2023
Figure 33. Americas PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 34. Americas PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 35. APAC PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 36. APAC PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 37. Europe PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 38. Europe PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 39. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 40. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 41. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 42. Americas PD-1&PD-L1 Immunotherapy Revenue Market Share by Country in 2023
Figure 43. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 44. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 45. United States PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 46. Canada PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 47. Mexico PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 48. Brazil PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 49. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Region in 2023
Figure 50. APAC PD-1&PD-L1 Immunotherapy Revenue Market Share by Regions in 2023
Figure 51. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 52. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 53. China PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 54. Japan PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 55. South Korea PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 56. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 57. India PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 58. Australia PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 59. China Taiwan PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 60. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 61. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Country in 2023
Figure 62. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 63. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 64. Germany PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 65. France PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 66. UK PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 67. Italy PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 68. Russia PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 69. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 70. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Market Share by Country in 2023
Figure 71. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 72. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 73. Egypt PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 74. South Africa PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 75. Israel PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 76. Turkey PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 77. GCC Country PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of PD-1&PD-L1 Immunotherapy in 2023
Figure 79. Manufacturing Process Analysis of PD-1&PD-L1 Immunotherapy
Figure 80. Industry Chain Structure of PD-1&PD-L1 Immunotherapy
Figure 81. Channels of Distribution
Figure 82. Global PD-1&PD-L1 Immunotherapy Sales Market Forecast by Region (2025-2030)
Figure 83. Global PD-1&PD-L1 Immunotherapy Revenue Market Share Forecast by Region (2025-2030)
Figure 84. Global PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Type (2025-2030)
Figure 85. Global PD-1&PD-L1 Immunotherapy Revenue Market Share Forecast by Type (2025-2030)
Figure 86. Global PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Application (2025-2030)
Figure 87. Global PD-1&PD-L1 Immunotherapy Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of PD-1&PD-L1 Immunotherapy
Figure 2. PD-1&PD-L1 Immunotherapy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1&PD-L1 Immunotherapy Sales Growth Rate 2019-2030 (Units)
Figure 7. Global PD-1&PD-L1 Immunotherapy Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. PD-1&PD-L1 Immunotherapy Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of PD-1 Inhibitors
Figure 10. Product Picture of PD-L1 Inhibitors
Figure 11. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type in 2023
Figure 12. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2019-2024)
Figure 13. PD-1&PD-L1 Immunotherapy Consumed in Non-Small Cell Lung Cancer
Figure 14. Global PD-1&PD-L1 Immunotherapy Market: Non-Small Cell Lung Cancer (2019-2024) & (Units)
Figure 15. PD-1&PD-L1 Immunotherapy Consumed in Esophageal Cancer
Figure 16. Global PD-1&PD-L1 Immunotherapy Market: Esophageal Cancer (2019-2024) & (Units)
Figure 17. PD-1&PD-L1 Immunotherapy Consumed in Urothelial Carcinoma
Figure 18. Global PD-1&PD-L1 Immunotherapy Market: Urothelial Carcinoma (2019-2024) & (Units)
Figure 19. PD-1&PD-L1 Immunotherapy Consumed in Hepatocellular Carcinoma
Figure 20. Global PD-1&PD-L1 Immunotherapy Market: Hepatocellular Carcinoma (2019-2024) & (Units)
Figure 21. PD-1&PD-L1 Immunotherapy Consumed in Small Cell Lung Cancer
Figure 22. Global PD-1&PD-L1 Immunotherapy Market: Small Cell Lung Cancer (2019-2024) & (Units)
Figure 23. PD-1&PD-L1 Immunotherapy Consumed in Others
Figure 24. Global PD-1&PD-L1 Immunotherapy Market: Others (2019-2024) & (Units)
Figure 25. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2023)
Figure 26. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application in 2023
Figure 27. PD-1&PD-L1 Immunotherapy Sales Market by Company in 2023 (Units)
Figure 28. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Company in 2023
Figure 29. PD-1&PD-L1 Immunotherapy Revenue Market by Company in 2023 ($ Million)
Figure 30. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Company in 2023
Figure 31. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Geographic Region in 2023
Figure 33. Americas PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 34. Americas PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 35. APAC PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 36. APAC PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 37. Europe PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 38. Europe PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 39. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales 2019-2024 (Units)
Figure 40. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue 2019-2024 ($ Millions)
Figure 41. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 42. Americas PD-1&PD-L1 Immunotherapy Revenue Market Share by Country in 2023
Figure 43. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 44. Americas PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 45. United States PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 46. Canada PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 47. Mexico PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 48. Brazil PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 49. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Region in 2023
Figure 50. APAC PD-1&PD-L1 Immunotherapy Revenue Market Share by Regions in 2023
Figure 51. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 52. APAC PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 53. China PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 54. Japan PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 55. South Korea PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 56. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 57. India PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 58. Australia PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 59. China Taiwan PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 60. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 61. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Country in 2023
Figure 62. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 63. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 64. Germany PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 65. France PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 66. UK PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 67. Italy PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 68. Russia PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 69. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Country in 2023
Figure 70. Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Market Share by Country in 2023
Figure 71. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2024)
Figure 72. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2024)
Figure 73. Egypt PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 74. South Africa PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 75. Israel PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 76. Turkey PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 77. GCC Country PD-1&PD-L1 Immunotherapy Revenue Growth 2019-2024 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of PD-1&PD-L1 Immunotherapy in 2023
Figure 79. Manufacturing Process Analysis of PD-1&PD-L1 Immunotherapy
Figure 80. Industry Chain Structure of PD-1&PD-L1 Immunotherapy
Figure 81. Channels of Distribution
Figure 82. Global PD-1&PD-L1 Immunotherapy Sales Market Forecast by Region (2025-2030)
Figure 83. Global PD-1&PD-L1 Immunotherapy Revenue Market Share Forecast by Region (2025-2030)
Figure 84. Global PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Type (2025-2030)
Figure 85. Global PD-1&PD-L1 Immunotherapy Revenue Market Share Forecast by Type (2025-2030)
Figure 86. Global PD-1&PD-L1 Immunotherapy Sales Market Share Forecast by Application (2025-2030)
Figure 87. Global PD-1&PD-L1 Immunotherapy Revenue Market Share Forecast by Application (2025-2030)
More Publications
Global Pediatric Intensive Care Ventilators Market Growth 2023-2029
US$ 3,660.00
March 2023
108 pages
Global B/W Cardiovascular Ultrasound Imaging System Market Growth 2024-2030
US$ 3,660.00
December 2024
131 pages
Global Measles and Rubella (MR) Vaccine Market Growth 2025-2031
US$ 3,660.00
February 2025
75 pages
